Abstract: Sulfonylureas (SUs) such as glibenclamide, gliclazide, glimepiride, glipizide and gliquidone are one of the first oral medicines available for the treatment of type 2 diabetes and are widely used for the treatment of hyperglycaemia. The hepatic transporters, organic anion transporting polypeptide 1B1 (OATP1B1) and organic anion transporting polypeptide 1B3 (OATP1B3), play an important role in the disposition of a variety of drugs by mediating their uptake from blood into hepatocytes. Drug-drug interactions mediated by OATP1B1/1B3 may result in the hepatic transporting change for drug substrates. The inhibitory effects of glibenclamide and glimepiride on sulfobromophthalein (BSP) uptake have been previously studied, and glibenclamide has been reported as the substrate of OATP1B3, but it remains unclear whether other SUs such as gliclazide, glipizide and gliquidone are substrates of OATP1B1 and OATP1B3. Here, we investigated the relationship between the five most commonly applied SUs (glibenclamide, gliclazide, glimepiride, glipizide, gliquidone) and OATP1B1 and OATP1B3. We performed uptake and inhibition assays in HEK293T cells stably expressing OATP1B1 or OATP1B3, respectively, and established a liquid chromatography-mass spectrometry (LC-MS) method for the simultaneous measurement of five SUs. We demonstrated that gliclazide and glimepiride are substrates of OATP1B1 and glibenclamide and glipizide are substrates of OATP1B3. We also confirmed the interaction between these SUs and rosuvastatin. No transporting was observed for gliquidone, suggesting that it is not a substrate of either transporter.
Type 2 diabetes mellitus, a type of metabolic disorder, is characterized by hyperglycaemia resulting from resistance or lack of insulin. One of the major approaches to control blood glucose levels is to take antidiabetic agents including insulin sensitizers (biguanides and thiazolidinediones), insulin secretagogues (sulfonylureas [SUs] and glinides), a-glucosidase inhibitors (e.g. acarbose) and dipeptidyl peptidase-IV inhibitors (e.g. sitagliptin). Among them, SUs were one of the first oral medicines available for the treatment of type 2 diabetes and were widely used for the treatment of hyperglycaemia [1] [2] [3] [4] [5] . However, the efficacy of them differs among individuals [6, 7] .
Many studies have been done to illustrate the roles of transporter in the absorption and disposition of compounds [8] [9] [10] [11] . OATP1B1 and OATP1B3 are hepatic uptake transporters that are expressed at the basolateral membrane of hepatocytes and are characterized by a wide range of diverse endogenous and exogenous substrates such as anticancer agents, HIV protease inhibitors and cardiac glycosides [12] [13] [14] [15] [16] [17] [18] . Competitive inhibition against transporters may occur when these substrates are taken together and thus lead to a change of drug concentration. These changes may increase the risk of adverse drug reactions. Therefore, it is necessary and crucial to explore the interactions between SUs and OATP1B1/1B3. Studies have shown that glibenclamide, reported as the substrate of OATP2B1, is also the substrate of OATP1B3 [19, 20] , and that glibenclamide and glimepiride will inhibit the uptake of sulfobromophthalein (BSP) at the level of OATP1B1 and OATP1B3 [21] , but it remains unclear whether other SUs including gliclazide, glipizide and gliquidone are substrates of OATP1B1 and OATP1B3, and information about the uptake difference among SUs is also limited. Besides, SUs are often combined with statins in order to manage the complicated conditions, hypercholesterolaemia combined with type 2 diabetes, which can undoubtedly increase the potential risks of drug-drug interaction (DDI). DDI can be caused by a range of factors among which the transport process of drugs is one of the most crucial determinants.
Here, we investigated the interaction of five commonly used SUs (glibenclamide, gliclazide, glimepiride, glipizide and gliquidone) with OATP1B1 and OATP1B3 and the potential drug-drug interactions between SUs and rosuvastatin, thereby providing a rationale for future guidance on rational drug use in clinic.
Materials and Methods
Chemicals and reagents. Glibenclamide, gliclazide, glimepiride, glipizide and gliquidone were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Rosuvastatin was supplied from Xindongfang Pharmaceutical Co., Ltd (Taizhou, China). Pitavastatin was provided by Dongyangguang Pharmaceutical Co., Ltd (Yidu, China). Glibenclamide, gliclazide, glimepiride, glipizide, gliquidone, rosuvastatin and pitavastatin were dissolved in dimethyl sulfoxide (DMSO; Solarbio Science & Technology Co., Ltd, Beijing, China). Ethyl acetate, acetonitrile and formic acid hypergrade for liquid chromatography-mass spectrometry (LC-MS) were purchased from Merck (Darmstadt, Germany). For all of Author for correspondence: Chunhua Xia, Clinical Pharmacology Institute, Nanchang University, Bayi road 461, Nanchang, 330006, China (e-mail xch720917@163.com). the experiments, water was purified with a Milli-Q system (Millipore Corporation, Billerica, MA, USA).
Cell culture. Human embryonic kidney (HEK293T) cells stably expressing OATP1B1 or OATP1B3 (HEK-OATP1B1 or HEK-OATP1B3, respectively) and vector control cells HEK-MOCK were kindly provided by Genechem Co., Ltd (Shanghai, China). For all of the experiments, HEK-OATP1B1, HEK-OATP1B3 and HEK-MOCK were cultured in high-glucose (4.5 g/L glucose) Dulbecco's modified Eagle's medium with 10% foetal bovine serum, 100 U/mL penicillin and 100 lg/mL streptomycin at 37°C under 5% CO 2 humidified air.
Uptake studies. HEK-OATP1B1, HEK-OATP1B3 and HEK-MOCK were seeded in 12-well plates at a density of 200,000 cells per well, and 1 mM sodium butyrate was added to the cells to induce protein expression [22, 23] After 24 hr, the medium was removed and cells were washed with pre-warmed (37°C) Hank's balanced salt solution (HBSS) containing 10 mM HEPES (HBSS-HEPES, 99:1, v/v). Subsequently, cells were incubated with a test solution containing rosuvastatin or SUs and their inhibitors at 37°C for the incubation times indicated in the figure legends. In order to terminate the incubation, the cells were washed with ice-cold HBSS-HEPES and lysed with water using multigelation. Intracellular accumulation of SUs and rosuvastatin (positive control group) was measured using a LC-MS method that is described in detail later. The protein concentration of each sample was determined using the BCA Protein Assay Kit (Vazyme Biotech Co., Ltd, Nanjing, China).
Sample preparation. Sample preparation was performed by liquidliquid extraction. An aliquot of 200 lL cell lysate spiked with 20 lL corresponding internal standard was added to a 1.5-mL stopper centrifuge tube. Then, 30 lL acetic acid and 800 lL ethyl acetate were added to the tube, shaken using a vortex mixer for 3 min. and centrifuged at 20, 000 g for 10 min. The supernatant was withdrawn and dried using a concentrated drying apparatus at 55°C for 30 min. The residue was redissolved in 200 lL mobile phase, and 5 lL was injected onto the column.
LC-MS analysis for SUs and rosuvastatin. The concentration of SUs (glibenclamide, gliclazide, glimepiride, glipizide gliquidone) and rosuvastatin in the cell lysate samples was measured using a LC-MS system equipped with a Shimadzu LC-20AB (Shimadzu Corporation, Kyoto, Japan) coupled to MS2010EV. Separation was performed using an analytical Shimadzu Pack VP-ODS C18 column (150 mm 9 2.0 mm) with a particle size of 5 lm.
The mobile phase for SUs, consisting of acetonitrile: 0.1% formic acid (80:20, v/v), was delivered at a flow rate of 0.2 mL/min. Gliquidone served as an internal standard when the other four SUs were being quantified, and glipizide was the internal standard when gliquidone was the test compound. Positive ion mode was used with selective ion monitoring (SIM) for the quantitative analysis of five different SUs. The detector voltage was set at +1.85 kV. The curved desolvation line (CDL) and the block heater temperature were set at 250°C and 200°C, respectively. The flow rate of drying gas (N 2 ) and nebulizing gas (N 2 ) was 2.0 L/min. and 1.5 L/min., respectively. The mass/charge ratio (m/z) of the adducts ([M+H] + ) is shown in table 1. Standards for the calibration curve were freshly prepared before each run. Good linearity was observed over the concentration range of 0.005-0.64 lM for glibenclamide, gliclazide and glimepiride, and a range of 0.01-1.28 lM for glipizide and gliquidone. The correlation coefficients (r) were >0.9900.
The mobile phase for rosuvastatin, running at a flow rate of 0.2 mL/min., consisted of 5 mM ammonium acetate (pH = 5.4) and acetonitrile (48:52, v/v). Pitavastatin was used as an internal standard. Mass spectroscopy was performed in negative ion mode, SIM, with a detector voltage of À1.85 kV, a CDL temperature of 250°C, a block heater temperature of 200°C, drying gas (N 2 ) flow rate of 2.0 L/min. and nebulizing gas (N 2 ) flow rate of 1.5 L/min. The mass/charge ratio (m/z) of rosuvastatin and pitavastatin ([M-H] À ) was 480.20 and 420.00, respectively. Good linearity was observed over a concentration range of 0.005-0.64 lM, and the correlation coefficients (r) were >0.9900.
Data process and statistical analysis. Transport kinetics was determined using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). The Michaelis-Menten constant (K m ) and maximum transport rate (V max ) for the substrates were calculated using the following Michaelis-Menten equation:
where V is the uptake velocity of the substrate (picomoles per milligram of protein per minute), V max is the maximum velocity (picomoles per milligram of protein per minute), [S] is the substrate concentration in the medium (micromolar) and K m is the Michaelis constant (micromolar). The concentration at which 50% inhibition of substrate uptake was obtained (IC 50 ) was estimated using SPSS 19.0. Uptake and inhibition assays were performed in quadruplicate, and all data were presented as means AE standard deviation (S.D.). The unpaired Student's t-test was used to assess the statistical significance, and p values smaller than 0.05 were considered statistically significant.
Results

Functional characterization of HEK-OATP1B1 and HEK-OATP1B3 cells.
The protein expression of HEK-OATP1B1 and HEK-OATP1B3 cells were verified by western blot analysis (Figure S1 ). To characterize the functions of OATP1B1 and OATP1B3, we measured the uptake of rosuvastatin, a substrate of these transporters, in HEK-OATP1B1 and HEK-OATP1B3 cells [24, 25] . The uptake in the HEK-OATPs induced with sodium butyrate was compared with that in the uninduced HEK-OATPs, and the uptake in the induced HEK-MOCK was compared with that in the uninduced HEK-MOCK. The results showed that rosuvastatin uptake in the induced HEK-OATPs was significantly higher than that in the uninduced HEK-OATPs, thus confirming that OATP1B1 and OATP1B3 had been expressed in the HEK293T cells and that sodium butyrate could enhance this expression. But no uptake differences were observed between the induced HEK-MOCK and the uninduced HEK-MOCK. (Figure S2 ). Time-and concentration-dependent uptake assays were performed in HEK-OATP1B1, HEK-OATP1B3 and HEK-MOCK cells ( Figure S3  and fig. 1 ). OATP1B1-or OATP1B3-mediated transport of 
Interaction between SUs and rosuvastatin.
We have demonstrated that gliclazide and glimepiride are substrates of OATP1B1 and glibenclamide and glipizide are substrates of OATP1B3. Next, we investigated the interaction of SUs with rosuvastatin which was the common substrate of OATP1B1 and OATP1B3 and was often combined with SUs. As shown in fig. 4 , the OATP1B1-mediated uptake of gliclazide and glimepiride and OATP1B3-mediated uptake of glibenclamide and glipizide were reduced to some extent when co-incubated with rosuvastatin, and vice versa. In HEK-OATP1B1 
Discussion
It is well accepted that transporters play an important role in the absorption and distribution of drugs. OATPs, mainly localized on the basolateral side of hepatic tissue, are crucial for the uptake of substances from the blood circulation into hepatocytes. This uptake process, recognized as the first step in hepatocellular elimination, may result in the alteration of plasma concentration of drugs, thereby leading to a risk of adverse reactions [26] . The main members of the OATP family, OATP1B1 and OATP1B3, have a broad substrate spectrum ranging from endogenously synthesized compounds (e.g., bile salts, steroid conjugates, hormones) to widely prescribed drugs such as statins, digitalis-like compounds and sorafenib [27] [28] [29] . Glibenclamide and glimepiride have been shown inhibitory effects on BSP, the substrate of OATP1B1 and OATP1B3 [21] , but information about the relationship between SUs and OATP1B1 or OATP1B3 is limited and needs to be fully defined. For these reasons, we studied whether OATP1B1 and OATP1B3 are involved in the uptake of SUs including glibenclamide, gliclazide, glimepiride, glipizide and gliquidone, and thus to help predict and to avoid potential OATP1B1-and OATP1B3-mediated drug-drug interactions.
We established an LC-MS method for the determination of five SUs (glibenclamide, gliclazide, glimepiride, glipizide and gliquidone) and identified the substrates of OATP1B1 (gliclazide and glimepiride) and OATP1B3 (glibenclamide and glipizide). According to the results of the concentration-dependent assays, we calculated the kinetic parameters K m and V max of SUs, and then compared them with those of rosuvastatin, the common substrate of OATP1B1 or OATP1B3 [30, 31] . As shown in fig. 1 , the K m values for OATP1B1-and OATP1B3-mediated rosuvastatin uptake were 34.54 AE 1.72 lM and 35.21 AE 2.04 lM, respectively, which were a little higher than the published reports (4-7.3 lM for OATP1B1 and 9.8 lM for OATP1B3). These discrepancies might result from the different experiment cells (Ho et al. used HeLa cells while we used HEK293T cells) and experiment conditions. Based on the same experiment conditions in our study, we found that glimepiride (K m , 10.02 AE 0.84 lM) had a higher affinity for OATP1B1 than rosuvastatin, and the affinity of gliclazide (K m , 30.18 AE 1.65 lM) was comparative with that of rosuvastatin. For OATP1B3, glibenclamide (K m , 15.36 AE 1.17 lM, V max 120.00 AE 7.55 pmol/mg protein/min.) had a stronger affinity than rosuvastatin, whereas the affinity of glipizide was a bit weaker (K m , 41.29 AE 1.93 lM; V max , 41.98 AE 2.14 pmol/mg protein/min.). These results suggest that gliclazide and glimepiride may be substrates of OATP1B1 and that glibenclamide and glipizide may be substrates of OATP1B3. Subsequent inhibition assays further confirmed these data, since the substrates were inhibited by OATP1B1 or OATP1B3 inhibitors. No uptake could be observed for gliquidone. These phenomena may result from the differences in their chemical structures. As shown in fig. 5 , an isoquinoline could be found in gliquidone despite the common group of sulfonylurea, the main active group for lowering blood glucose. The steric hindrance may have prevented it from binding OATP1B1 and OATP1B3. As for glibenclamide and glipizide, the presence of cyclohexyl may help their combination with OATP1B3. However, substituent attached to the cyclohexyl appears to weaken the affinity of SUs to OATP1B3 and the SU may tend to combine with OATP1B1 (e.g. glimepiride). For gliclazide, the presence of nitrogen base (N-) may block the combination with OATP1B3 and lead to the combination with OATP1B1. However, all these hypotheses need to be verified by computational analysis. Because SUs are often concomitantly prescribed with lipidaemia-modulating drugs in obese/overweight patients due to the combined prevalence of type 2 diabetes and hypercholesterolaemia [32] [33] [34] [35] , we studied the possible drug-drug interaction between SUs and rosuvastatin, which was one representative of lipidaemia-modulating drugs and was the common substrate of OATP1B1 and OATP1B3, in vitro. The results showed that they had inhibitory effects on each other. The uptake of SUs and rosuvastatin was reduced to some extent ( fig. 4) , which shed light on the fact that there might be competitive inhibition against transporters between them. However, the observed inhibitions were not strong enough. We supposed that these drugs might be permeating into the cells by passive diffusion in addition to the carrier-mediated uptake. Besides, it might also be related to some unspecific binding by suboptimal experimental procedures such as too few washing steps, since cell viability would be reduced when the washing steps were added. These reasons for the limited inhibition require a further exploration in the future.
As drug uptake transporter is one of the most important determinants for pharmacokinetics, drug-drug interactions resulted from the transporters may lead to a change in drug concentration, which increase the risks of adverse drug reactions in patients. Our studies in vitro indicated that there was a potential of interactions between SUs and rosuvastatin mediated by OATP1B1 or OATP1B3. But when taking in consideration protein binding of respective substances in human beings, such drug-drug interactions seem not to be significant or clinically relevant. Indeed, the plasma concentrations of drugs in human beings were not always as high as in vitro, and this might be the reason for a possible negative outcome of DDI study in patients. However, this was not the only possibility. Because both SUs and rosuvastatin have a high affinity for plasma proteins [36, 37] , there might be a competitive binding to the plasma proteins between these drugs, thus resulting in an increasing free plasma concentration. All these changes might lead to the change of drug efficacy and increase the risks of adverse drug reactions. Additionally, since the expression of OATPs might not be exactly the same between the cell model in this study and human hepatocytes, this discrepancy might also lead to the difference between in vivo and in vitro study. Therefore, a clinical study on the potential interactions between SUs and rosuvastatin in patients requires to be performed to further confirm that SUs and rosuvastatin would also interact with each other in human beings. What is more, transport activity may be associated with the polymorphic variant of transporters. Whether the individual difference that occurs in type 2 diabetic patients taking SUs results from gene polymorphism of transporters also needs to be further studied.
In summary, our results showed gliclazide and glimepiride were the substrates of OATP1B1 and and glibenclamide and glipizide were the substrates of OATP1B3. Gliquidone was not a substrate of either transporter. There was a potential interaction between SUs and rosuvastatin mediated by OATP1B1 or OATP1B3.
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Additional Supporting Information may be found online in the supporting information tab for this article: Figure S1 . Western blot analysis of protein expression in HEK-OATP1B1 (A) and HEK-OATP1B3 (B). Figure S2 . The uptake of rosuvastatin in HEK-OATP1B1 (A, incubated for 10 min.), HEK-OATP1B3 (B, incubated for 5 min.) and HEK-MOCK in the absence or presence of sodium butyrate for 24 hr (n = 4, mean AE S.D.). Figure S3 . Time-dependent uptake of rosuvastatin mediated by OATP1B1 (A) and OATP1B3 (B). Figure S4 . Time-dependent uptake of SUs in HEK-OATP1B1 (A, C, E, G and I) and HEK-OATP1B3 (B, D, F, H and J) cells.
